Published in Hepatology on August 01, 2003
A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Health (2011) 1.27
Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. World J Gastroenterol (2009) 1.17
Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther (2009) 1.08
Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol (2006) 1.08
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther (2012) 1.07
Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep (2008) 0.90
Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation. Virol J (2005) 0.88
ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS. SIAM J Appl Math (2009) 0.87
Hepatitis C viral kinetics: the past, present, and future. Clin Liver Dis (2013) 0.87
The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection. Korean J Hepatol (2012) 0.78
Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response. PLoS One (2014) 0.77
Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment. World J Gastroenterol (2013) 0.77
Immunomodulation therapy in children with chronic hepatitis B. J Natl Med Assoc (2006) 0.76
Noninvasive monitoring of hepatic damage from hepatitis C virus infection. Comput Math Methods Med (2011) 0.75
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Kinetics of influenza A virus infection in humans. J Virol (2006) 3.78
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol (2007) 3.24
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature (2004) 2.74
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology (2003) 2.50
Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis (2006) 2.44
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
The complexity of complexes in signal transduction. Biotechnol Bioeng (2003) 2.20
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol (2003) 2.03
Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol (2010) 2.02
Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl (2006) 2.01
Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology (2007) 2.00
CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog (2010) 1.99
The year-long effect of HIV-positive test results on pregnancy intentions, contraceptive use, and pregnancy incidence among Malawian women. J Acquir Immune Defic Syndr (2008) 1.94
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS (2010) 1.89
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol (2007) 1.89
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology (2011) 1.87
Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol (2003) 1.87
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A (2002) 1.82
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78
Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol (2004) 1.77
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
ON IDENTIFIABILITY OF NONLINEAR ODE MODELS AND APPLICATIONS IN VIRAL DYNAMICS. SIAM Rev Soc Ind Appl Math (2011) 1.69
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology (2006) 1.69
Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 1.68
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol (2005) 1.60
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol (2011) 1.57
Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol (2009) 1.56
Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull Math Biol (2008) 1.56
Drug resistance and influenza pandemics. Lancet (2002) 1.55
HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55
Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.54
Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol (2006) 1.53
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol (2008) 1.51
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol (2008) 1.51
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol (2008) 1.49
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology (2005) 1.47
HIV-1 infection and low steady state viral loads. Bull Math Biol (2002) 1.46
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics (2010) 1.45
Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis (2013) 1.43
Agent-based modeling of host-pathogen systems: The successes and challenges. Inf Sci (Ny) (2009) 1.43
Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J Virol (2004) 1.43
Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med (2008) 1.42
Complete genetic linkage can subvert natural selection. Proc Natl Acad Sci U S A (2007) 1.42
Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci (2002) 1.41
Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol (2006) 1.41
Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol (2008) 1.39
Generalizability and scalability of HIV 'treatment as prevention'. AIDS (2013) 1.39
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol (2004) 1.39
Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology (2006) 1.38
HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci U S A (2005) 1.36
Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A (2011) 1.36
Quantifying T lymphocyte turnover. J Theor Biol (2013) 1.35
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol (2006) 1.31
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS (2003) 1.30
Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol (2002) 1.30
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol (2011) 1.28
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis (2003) 1.27
Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol (2012) 1.26